Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.

Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, Ebert BL, Griffin JD, Frank DA.

Blood. 2011 Mar 24;117(12):3421-9. doi: 10.1182/blood-2009-11-255232. Epub 2011 Jan 13.


Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit.

Smart CE, Wronski A, French JD, Edwards SL, Asselin-Labat ML, Waddell N, Peters K, Brewster BL, Brooks K, Simpson K, Manning N, Lakhani SR, Grimmond S, Lindeman GJ, Visvader JE, Brown MA.

Oncogene. 2011 Mar 31;30(13):1597-607. doi: 10.1038/onc.2010.538. Epub 2010 Dec 6.


Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden.

Klover PJ, Muller WJ, Robinson GW, Pfeiffer RM, Yamaji D, Hennighausen L.

Neoplasia. 2010 Nov;12(11):899-905.


Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.

Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z.

Cancer Cell. 2010 Nov 16;18(5):423-35. doi: 10.1016/j.ccr.2010.10.025.


Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer.

Gu L, Zhu XH, Visakorpi T, Alanen K, Mirtti T, Edmonston TB, Nevalainen MT.

Anal Cell Pathol (Amst). 2010;33(2):55-9. doi: 10.3233/ACP-CLO-2010-0534.


PTP1B suppresses prolactin activation of Stat5 in breast cancer cells.

Johnson KJ, Peck AR, Liu C, Tran TH, Utama FE, Sjolund AB, Schaber JD, Witkiewicz AK, Rui H.

Am J Pathol. 2010 Dec;177(6):2971-83. doi: 10.2353/ajpath.2010.090399. Epub 2010 Oct 15.


Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.

Sakamoto K, Triplett AA, Schuler LA, Wagner KU.

Oncogene. 2010 Sep 30;29(39):5359-69. doi: 10.1038/onc.2010.274. Epub 2010 Jul 19.


Stat5 promotes survival of mammary epithelial cells through transcriptional activation of a distinct promoter in Akt1.

Creamer BA, Sakamoto K, Schmidt JW, Triplett AA, Moriggl R, Wagner KU.

Mol Cell Biol. 2010 Jun;30(12):2957-70. doi: 10.1128/MCB.00851-09. Epub 2010 Apr 12.


Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation.

Vafaizadeh V, Klemmt P, Brendel C, Weber K, Doebele C, Britt K, Grez M, Fehse B, Desriviéres S, Groner B.

Stem Cells. 2010 May;28(5):928-38. doi: 10.1002/stem.407.


Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten.

Barbieri I, Pensa S, Pannellini T, Quaglino E, Maritano D, Demaria M, Voster A, Turkson J, Cavallo F, Watson CJ, Provero P, Musiani P, Poli V.

Cancer Res. 2010 Mar 15;70(6):2558-67. doi: 10.1158/0008-5472.CAN-09-2840. Epub 2010 Mar 9.


Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene.

Barbieri I, Quaglino E, Maritano D, Pannellini T, Riera L, Cavallo F, Forni G, Musiani P, Chiarle R, Poli V.

Mol Carcinog. 2010 Feb;49(2):114-20. doi: 10.1002/mc.20605.


Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A.

Yamaji D, Na R, Feuermann Y, Pechhold S, Chen W, Robinson GW, Hennighausen L.

Genes Dev. 2009 Oct 15;23(20):2382-7. doi: 10.1101/gad.1840109.


Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer.

Larsson AM, Jirström K, Fredlund E, Nilsson S, Rydén L, Landberg G, Påhlman S.

Clin Cancer Res. 2009 Sep 1;15(17):5552-9. doi: 10.1158/1078-0432.CCR-08-3014. Epub 2009 Aug 25.


Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression.

Ranger JJ, Levy DE, Shahalizadeh S, Hallett M, Muller WJ.

Cancer Res. 2009 Sep 1;69(17):6823-30. doi: 10.1158/0008-5472.CAN-09-1684. Epub 2009 Aug 18.


Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.

Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ; kConFab., Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ.

Nat Med. 2009 Aug;15(8):907-13. doi: 10.1038/nm.2000. Epub 2009 Aug 2.


Targeting janus kinase 2 in Her2/neu-expressing mammary cancer: Implications for cancer prevention and therapy.

Sakamoto K, Lin WC, Triplett AA, Wagner KU.

Cancer Res. 2009 Aug 15;69(16):6642-50. doi: 10.1158/0008-5472.CAN-09-0746. Epub 2009 Jul 28.


Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.

Crouch Z, DeSantis ER.

Am J Health Syst Pharm. 2009 Jul 1;66(13):1180-5. doi: 10.2146/ajhp080214. Review.


Janus kinases in immune cell signaling.

Ghoreschi K, Laurence A, O'Shea JJ.

Immunol Rev. 2009 Mar;228(1):273-87. doi: 10.1111/j.1600-065X.2008.00754.x. Review.


Mutational analysis of JAK1 gene in human hepatocellular carcinoma.

Xie HJ, Bae HJ, Noh JH, Eun JW, Kim JK, Jung KH, Ryu JC, Ahn YM, Kim SY, Lee SH, Yoo NJ, Lee JY, Park WS, Nam SW.

Neoplasma. 2009;56(2):136-40.


Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.

Renner O, Blanco-Aparicio C, Grassow M, Cañamero M, Leal JF, Carnero A.

Cancer Res. 2008 Dec 1;68(23):9643-53. doi: 10.1158/0008-5472.CAN-08-1539.

Supplemental Content

Support Center